Oncotarget
Press Release: Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer
Aug 2, 2022
Researchers Marina Baretti, Qingfeng Zhu, Wei Fu, Jeffrey Meyer, Hao Wang, Robert A. An discuss the synergy between radiotherapy and immune checkpoint inhibitors in rectal cancer. They delve into the impact of neoadjuvant chemoradiotherapy on immune factors, aiming to enhance anti-tumor immune responses and personalized treatment strategies.
06:27
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Synergy between radiotherapy and PD1, PDL1 pathway may induce antitumor immune response in rectal cancer.
- Higher mucin expression post NCRT and non-significant difference in PDL1 expression highlights need for further mechanistic investigations in rectal cancer.
Deep dives
Impact of Neo-Advent CRT on CD8 Positive TILs and PDL1 Expression in Rectal Cancer
The research paper explores the synergy between radiotherapy and PD1, PDL1 pathway inhibition in inducing anti-tumor immune response in rectal cancer. Researchers investigated the changes in CD8 positive tumor infiltrating lymphocytes, PDL1 expression, and muicin levels in rectal cancer patients post neo-advent chemo radiotherapy. While synergistic effects of CRT and PD1, PDL1 immunotherapy have been observed in various cancers, the study aims to evaluate the impact of NCRT on TME alterations in rectal cancer.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
